DeCure for Arteriovenous malformations of the brain
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for arteriovenous malformations of the brain — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleArteriovenous malformations of the brain maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for arteriovenous malformations of the brain is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
endoglin (ENG) — ENG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5I04 · 2.42 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
In a 2005 animal study, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) were injected into the optic tectum of 4-day-old quail embryos. VEGF caused expansion of brain blood vessels, Ang-2 caused retraction, and the combination produced retroorbital or intraventricular haemorrhage with enlarged, dysmorphic vessels and extended filopodia. The authors suggested these observations might help develop a better model of brain arteriovenous malformations, but no human data or therapeutic intervention was tested.
A 2020 review of non-hereditary brain arteriovenous malformations states that intracranial haemorrhage remains a substantial cause of morbidity and mortality. The pathogenesis of sporadic brain arteriovenous malformations is still not well elucidated, despite investigation of genetic factors, microvascular architecture, angiogenic factors, and signalling pathways. The review offers no concrete survival or response rates, and no drug is identified as effective.
A 2010 review (published in Japanese, focused on nursing after hip replacement) notes that brain arteriovenous malformations are increasingly detected by modern imaging, present in young individuals, and cause cerebral haemorrhages or seizure disorders. It mentions advances in surgical, endovascular, and radiation therapy, but provides no drug-based treatment data.
No drug has been shown to treat or prevent brain arteriovenous malformations in humans. What is missing is a validated animal model that reliably mimics the human condition, a clear molecular target for sporadic cases, and any clinical trial testing a repurposed or novel agent. Patient stratification by genetic or angiogenic profile has not been attempted.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of neurosurgery · 2005 · 20 citations
Angiogenesis in the brain during development: the effects of vascular endothelial growth factor and angiopoietin-2 in an animal model
AbstractOBJECT: The goal of this study was to examine the roles of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in the formation of blood vessels in the brain in a developmental animal model not routinely used for such a study. METHODS: Either VEGF, Ang-2, or a combination of the two factors were injected into the optic tectum of 4-day-old quail embryos. Immunohistochemical analysis and laser confocal microscopy were used to observe the effects on endothelial cells in the brain. Vascular endothelial growth factor and Ang-2 had very different effects on the development of blood vessels; the former caused expansion and the latter retraction of these vessels. Treatment with a combination of VEGF and Ang-2 caused retroorbital or intraventricular hemorrhage, and brain blood vessels appeared enlarged and dysmorphic, with dramatically extended filopodia. CONCLUSIONS: Some of these observations may provide insight into how one may develop a better model of brain arteriovenous malformations.
Interventional Neuroradiology · 2020 · 14 citations · open access
Pathogenesis of non-hereditary brain arteriovenous malformation and therapeutic implications
AbstractBrain arteriovenous malformations have a high risk of intracranial hemorrhage, which is a substantial cause of morbidity and mortality in patients with brain arteriovenous malformations. Although a variety of genetic factors leading to hereditary brain arteriovenous malformations have been extensively investigated, their pathogenesis is still not well elucidated, especially in sporadic brain arteriovenous malformations. The authors have reviewed the updated data of not only the genetic aspects of sporadic brain arteriovenous malformations, but also the architecture of microvasculature, the roles of the angiogenic factors, and the signaling pathways. This knowledge may allow us to infer the pathogenesis of sporadic brain arteriovenous malformations and develop pre-emptive treatments for them.
AbstractBrain arteriovenous malformations are currently attracting increasing attention among clinicians as modern brain imaging techniques facilitate both diagnostic and follow-up evaluation. Their frequent presentation in young individuals, at times with flagrant clinical effects caused by cerebral hemorrhages or seizure disorders, keeps clinicians alert to any improvement in treatment strategies. Recent technical advances in surgical, endovascular, and radiation therapy add to the constantly accumulating data on clinical features, natural course, and treatment outcome in adult arteriovenous malformation patients. This review focuses on new concepts in arteriovenous malformation etiology, classification, treatment, and study approaches.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
